The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Ropeginterferon alfa-2b in patients with early/lower-risk primary MF
|
Pegylated interferon alfa is recommended for the treatment of patients with lower-risk PMF who are symptomatic, based on phase II non-randomized studies and expert opinion. Ropeg shows promise in achieving durable hematologic responses, including normalization of blood counts and control of PMF-related symptoms, and has the potential to modify disease progression. In a recent publication in Annals of Hematology, Abu‑Zeinah et al. outline a planned randomized phase III trial designed to assess the efficacy and safety of ropeg in patients with early/lower-risk PMF.1
|
| Key learnings |
|
This new phase III trial (NCT06468033) will evaluate the efficacy and safety of ropeg in 150 patients with early/lower-risk PMF, randomized 2:1 to receive either ropeg or placebo. |
|
Co-primary endpoints include clinically relevant complete hematologic response and symptom endpoint (no progression of clinical symptoms) at 56 weeks. |
|
Secondary endpoints include PFS/EFS, molecular response in driver or relevant coexisting gene mutations, bone marrow response, and safety. |
|
The study will provide important data for the treatment of early/lower-risk PMF for which an anti-clonal, disease-modifying agent is highly needed. |
|
Ropeg could address a critical unmet need in this patient population by offering a safe and effective option that reduces thrombosis risk and delays disease progression. |
Abbreviations: EFS, event-free survival; MF, myelofibrosis; MPN, myeloproliferative neoplasm; PFS, progression-free survival; PMF, primary myelofibrosis; ropeg, ropeginterferon alfa-2b.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
On average, how many patients with myelofibrosis do you see in a month?
